February 9, 2026 USA
BioStock: Diamyd Medical strengthens position in the US – patent approval in sight
Diamyd Medical has received a Notice of Allowance from the U.S. Patent Office for a patent covering the intralymphatic administration of its diabetes drug candidate retogatein (rhGAD65). Once granted, the patent is expected to provide patent protection until 2035 and further strengthen the company’s intellectual property position in the U.S., aligned with the ongoing Phase 3 study, with an interim efficacy readout anticipated by the end of March 2026.
Read the article here
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.